Alembic Pharmaceuticals Limited Overview
Alembic Pharmaceuticals is a mid-sized, promoter-controlled, vertically integrated Indian generics company with a 119-year group heritage and a deliberately balanced "four-engine" revenue base: India branded formulations (33% of FY26 revenue), US generics (30%), ex-US international generics (20%) and active pharmaceutical ingredients (16%). It ranks 21st in the Indian Pharmaceutical Market with 1.1% share and 17th by prescription volume, anchored by category-leading macrolide brands (Azithral, Althrocin, Roxid) and a fast-growing animal-health franchise. Internationally, it has built one of the deeper ANDA portfolios among Indian mid-caps — 279 filings, 244 approvals and 185 launched US products as of June 2026 — backed by USFDA-inspected oral-solid, oncology, injectable, ophthalmic and dermatology plants in Gujarat. After a 2020–2025 phase of heavy capex and R&D that compressed returns, Alembic is now pivoting to monetisation: accelerated US launches, Paragraph IV first-to-file opportunities, and a nascent US branded women's-health business (Pivya, Nuvessa).
Company self-description. In every 2026 results press release, Alembic describes itself as a vertically integrated research and development pharmaceutical company, active in healthcare since 1907, headquartered in India, which manufactures and markets generic pharmaceutical products worldwide; its research and manufacturing facilities are approved by regulators in multiple developed markets including the USFDA, and it considers itself one of the leaders in branded generics in India [PR-Q4FY26; PR-Q1FY27]. It reports a single operating segment, "Pharmaceuticals" [Q1 FY27 results filing].
Independent characterisation. Functionally, Alembic operates four distinct businesses that share a common R&D and manufacturing backbone:
-
India Branded Formulations (incl. Animal Health) — prescription-driven branded generics sold through a ~5,500–5,800-strong field force to ~246,000 prescribers [IP-Q1FY27]. The portfolio is roughly 57% "speciality" (chronic and specialist-prescribed therapies such as cardiology, anti-diabetes, gynaecology, ophthalmology, gastro), 21% acute (anti-infectives, cough and cold) and 22% animal health (Q1 FY27 mix) [IP-Q1FY27]. 13% of the portfolio falls under India's National List of Essential Medicines (NLEM) price controls [IP-Q1FY27].
-
US Generics (and, since March 2026, US Branded) — a direct US front-end (Alembic Pharmaceuticals Inc., New Jersey) selling oral solids, dermatologicals, ophthalmics, injectables (incl. oncology) to wholesalers, retail chains, GPOs. In Q4 FY26, a branded specialty unit, Alembic Therapeutics LLC (Bedminster, NJ), launched Pivya (pivmecillinam) for uncomplicated UTI and in June 2026 acquired Nuvessa (metronidazole vaginal gel 1.3%) [PR-Q4FY26; GlobeNewswire 9 Jun 2026].
-
Ex-US International Generics — partner-led and, increasingly, own-subsidiary distribution in Europe, Canada, Australia, Brazil, Chile, South Africa, UAE, Southeast Asia (new subsidiaries in Thailand, the Philippines, Germany) and a new Canadian associate (45%) [IP-Q1FY27].
-
API — merchant sales of active ingredients to customers in 60+ countries, plus captive supply to its own formulations; 152 cumulative US DMFs [IP-Q1FY27].
Revenue model mix. Essentially 100% product sales. Licensing, royalty, service or subscription revenue is not separately disclosed and is immaterial on available evidence. Within product sales, the mix in FY26 was: branded (India + animal health) 33.5%, generic formulations exports 50.4% (US 30.0%, ex-US 20.3%), API 16.2% [PR-Q4FY26].
Value-chain position. Fully integrated from API synthesis (Panelav, Karkhadi) through finished-dose manufacturing (5 USFDA-inspected formulation sites plus a WHO-certified domestic plant at Indore/Pithampur) to front-end marketing in India and the US. In-house bioequivalence (BE) clinical facility at Vadodara supports ANDA filings [Reg30, 13 Jul 2026]. This integration gives cost control and supply security but makes the business capital-intensive (FY26 PP&E INR 34.8 Bn plus CWIP INR 6.3 Bn) [S&P/SA].
Customer types. Indian doctors (prescription influence), distributors/stockists and chemists (India); veterinarians, poultry integrators and livestock farmers (animal health); US wholesalers (consolidated buying groups), retail pharmacy chains, GPOs and specialty pharmacies (US); in-market partners and tender buyers (ex-US); generic formulators globally (API).
End-markets served. Human therapeutics (anti-infective, cardiology, diabetes, gynaecology, gastro, ophthalmology, respiratory/cough-cold, CNS, oncology, dermatology, women's health), veterinary (livestock, poultry, companion animals) and bulk-drug intermediates/APIs.
Strategy
Stated strategy themes (latest disclosures). From the FY26/Q1 FY27 investor materials and management commentary, Alembic's strategy rests on the following stated themes [IP-Q1FY27 "Value Proposition"; PR-Q4FY26; PR-Q1FY27]:
-
Expanding the US product portfolio and evolving the pipeline toward complex platforms and specialty segments (injectables, oncology, ophthalmics, derma, peptides).
-
Building a "focused branded specialty portfolio in the US", beginning with women's health (Pivya, Nuvessa). CFO G. Krishnan has framed this as a "twin engine" alongside generics, in response to persistent generic price pressure [Mint via AskFuzz, May 2026].
-
Developing a specialty drug pipeline for India and growing the India branded business through prescription-led brand building.
-
Exploring opportunities in injectables.
-
Strengthening presence in Canada, South Africa, LATAM and the Middle East; established presence in Chile and UAE.
-
Supplying APIs to 60+ countries with focus on cost efficiency.
-
Maintaining a consistent dividend payout.
-
R&D focused on peptide development and increased ANDA filings [IP-Q1FY27].
Strategic initiatives — last 24 months.
Cost programmes. No formal cost-reduction programme with quantified targets has been announced. Management emphasises operating leverage and API cost efficiency [IP-Q1FY27].
Medium-term financial targets/guidance.
Products & Services
5A. India Branded — Human (Top brands, IQVIA MAT Jun-26) [IP-Q1FY27]
| Brand | Molecule / therapy (where known) | Category rank | Market share (%) |
|---|---|---|---|
| Azithral | Azithromycin — anti-infective | 1 | 34.8 |
| Crina-NCR | Norethisterone — gynaecology | 1 | 31.7 |
| Althrocin | Erythromycin — anti-infective | 1 | 87.8 |
| Roxid | Roxithromycin — anti-infective | 1 | 95.1 |
| Deltone | Gynaecology/hormonal | 1 | 52.0 |
| Gerijoint | Joint/orthopaedic supplement | 1 | 33.9 |
| Elata | — | 1 | 52.4 |
| Cetanil | — | 2 | 6.9 |
| Gestofit SR | Progesterone — gynaecology | 2 | 18.5 |
| Lactonic | — | 2 | 22.9 |
| Estroplus | Gynaecology/hormonal | 2 | 15.4 |
| Isofit SR | Isoxsuprine — obstetrics | 2 | 35.1 |
| Travisight | Ophthalmology (travoprost family) | 2 | 19.8 |
| Unigolix | Gynaecology (relugolix combination) | 2 | 13.8 |
| Freego | — | 2 | 8.8 |
| Wikoryl | Cough & cold combination | 3 | 10.9 |
| Isofit | Isoxsuprine | 3 | 5.6 |
| Brozeet-LS | Respiratory (levosalbutamol/ambroxol) | 3 | 6.4 |
| Ulgel | Gastro (antacid) | 3 | 7.9 |
| Cloff | Cough preparation | 3 | 11.2 |
| Veldrop | Ophthalmology | 3 | 4.5 |
| Etrik | — | 4 | 5.5 |
| Bilambic-M | Anti-allergic combination (bilastine/montelukast) | 4 | 5.8 |
| Ovigyn DH | Gynaecology | 4 | 11.0 |
| Tellzy | Cardiology (telmisartan family) | 5 | 3.8 |
| Sharkoferrol | Haematinic (human/vet) | 5 | 5.1 |
| Bladmir | Urology (mirabegron) | 5 | 6.5 |
| Harmoni | — | 5 | 5.1 |
| Therapy | Share (%) |
|---|---|
| Animal health | 22 |
| Anti-infective | 15 |
| Gynaecology | 15 |
| Cardiology | 14 |
| Others | 11 |
| Anti-diabetic | 10 |
| Gastrology | 7 |
| Cough & cold | 6 |
Additional facts: five flagship brands exceed INR 1 Bn annual sales; total prescriptions 137.6 Mn (MAT Jun-26) vs 131.3 Mn a year earlier; prescriber base rose from 237,000 to 246,000 [IP-Q1FY27]. Total brands: 208 [IP-Q1FY27].
Therapy mix — India Branded, Q1 FY27 (% of India Branded revenue) [IP-Q1FY27].
New launches: 2 products in Q4 FY26 and 3 in Q1 FY27 [PR-Q4FY26; PR-Q1FY27]. Pricing: MRP-based branded generics; 13% of portfolio under NLEM price control.
5B. India Branded — Animal Health [IP-Q1FY27]
| Item | Detail |
|---|---|
| Segments | Livestock, poultry, companion animals |
| Leadership | Market leader in haematinics and antibiotics |
| Named brands | Sharkoferrol, Moxel, Xceft, Mceft |
| Brand tiers by annual sales | 6 brands > INR 300 Mn; 3 brands INR 200–300 Mn; 5 brands INR 100–200 Mn; 26 brands INR 20–100 Mn |
| Q1 FY27 mix | Feed supplement 34%, antibiotic 37%, tonic 10%, supportive therapy 10%, antiparasitic 9% |
5C. US Formulations — Generics [IP-Q1FY27]
| Dosage form | Approved ANDAs |
|---|---|
| Oral solids | 164 |
| Dermatology | 33 |
| Ophthalmic | 23 |
| Injectable | 22 |
| Inhalation | 2 |
| Product | Reference brand (RLD) | Approval type / date | IQVIA US market size | Notes / source |
|---|---|---|---|---|
| Ticagrelor Tablets 60 mg | Brilinta (AstraZeneca) | Final (2025) | Not captured | Cardiovascular; cumulative 227 approvals at the time |
| Macitentan Tablets 10 mg | Opsumit | Final (2025) | USD 1,180 Mn | PAH [Simply Wall St summary] |
| Carbamazepine ER Tablets 100/200/400 mg | Tegretol-XR (Novartis) | Final (2025) | Not captured | CNS |
| Tretinoin Cream 0.025% | Retin-A | Final (2025) | USD 94 Mn | Derma |
| Paroxetine ER Tablets 12.5 mg (sANDA) | Paxil CR | Final (~early 2026) | Not captured | 235 approvals at the time |
| Dapagliflozin Tablets 5/10 mg | Farxiga (AstraZeneca) | Final, 7 Apr 2026 | — | Eligible for 180-day shared first-to-file exclusivity |
| Fingolimod Capsules 0.5 mg | Gilenya | Final, 25 Apr 2026 | USD 145 Mn | MS |
| Levothyroxine Sodium Tablets | Synthroid class | Final, 22 May 2026 | Not captured | Large-volume thyroid generic |
| Haloperidol Tablets 1/2/5/10/20 mg | Haldol | Final, 5 Jun 2026 | USD 27 Mn | 240 approvals |
| Larotrectinib Capsules 25/100 mg | Vitrakvi (Bayer) | Tentative, 11 Jun 2026 | USD 91 Mn | Sole first applicant with Para IV — potential 180-day exclusivity |
| Tretinoin Cream 0.05% | Retin-A (Bausch) | Final, 12 Jun 2026 | Not captured | 242 approvals |
| Binimetinib Tablets 45 mg (and earlier 15 mg) | Mektovi | Tentative, 19 Jun 2026 | ~USD 26 Mn (reported) | Potential 180-day exclusivity |
| Oseltamivir Phosphate Oral Suspension 6 mg/mL | Tamiflu | Final, 26 Jun 2026 | Not captured | Antiviral |
| Dapsone Gel 5% | Aczone | Final, 29 Jun 2026 | Not captured | 244 approvals |
| Prucalopride Tablets 1/2 mg | Motegrity (Takeda) | Final, 28 Jul 2026 | USD 100 Mn | 245 approvals |
| Ciprofloxacin/Dexamethasone Otic Suspension 0.3%/0.1% | Ciprodex | Final, ~Oct 2026 | Not captured | Latest approval [EquityBulls, Oct 2026] |
| Methotrexate Injection USP | — | Final (2026) | Not captured | Injectables |
| Diltiazem HCl Tablets | Cardizem (Bausch) | Final (2025–26) | Not captured | Cardiovascular |
| Olaparib Tablets 100/150 mg (partner NATCO) | Lynparza | Tentative to partner, 18 Jul 2026 | Not captured | Alembic to market in US per reports |
Approved ANDAs by dosage form (cumulative, June 2026; total 244 incl. 20 tentative).
Cumulative: 279 ANDA filings, 244 approvals, 185 products launched; 7 launches in Q1 FY27; 15+ launches guided for FY27 [IP-Q1FY27]. In July 2025 the US unit described its portfolio as 160+ molecules and 413 products (SKUs) [Craig Salmon statement, Jul 2025].
Notable US approvals, Jan 2025 – Oct 2026 (product by product).
Earlier anchor products include aripiprazole (2015 launch), lamotrigine ER (2024, USD 163 Mn), paliperidone ER (2024, USD 48 Mn), bosentan, deferasirox, pantoprazole injection, doxorubicin injection and bromfenac ophthalmic.
5D. US Formulations — Branded (Alembic Therapeutics LLC)
| Product | Description | Status | Pricing |
|---|---|---|---|
| Pivya (pivmecillinam) tablets | First-line oral antibiotic for uncomplicated UTI in adult women; FDA-approved April 2024; acquired with Utility Therapeutics | Commercial launch Q4 FY26 (March 2026); management reported a completed "soft launch" with encouraging response [IP-Q1FY27] | — |
| MEC (mecillinam, IV) | Under development for complicated UTI | Development; timeline not disclosed | — |
| Nuvessa (metronidazole vaginal gel 1.3%) | Single-dose pre-filled applicator, ~5 g gel with 65 mg metronidazole, for bacterial vaginosis in females ≥12 years; acquired from Exeltis USA | Acquired 9 Jun 2026; sold via retail and specialty pharmacy | Terms and price not disclosed |
5E. Ex-US Formulations
Product-level detail is not publicly disclosed. Operations run through partnerships in Europe, Canada, Australia, Brazil, Chile and South Africa, with own presence in Chile and the UAE and new subsidiaries in Thailand, the Philippines, Germany and Dubai [IP-Q1FY27; Reg30].
5F. API
152 cumulative US DMFs (3 filed in Q1 FY27, 2 in Q3 FY26) [IP-Q1FY27; IP-Q3FY26]. Molecule-level catalogue is not publicly disclosed in reviewed documents.
Financial Narrative
All consolidated. Primary source for FY22–FY26 line items: [S&P/SA] standardised from company filings, cross-checked to company press releases and the Q1 FY27 investor presentation. Where company-reported figures differ, both are shown.
6A. Income statement: notes and sources
Notes: Company-reported EBITDA for FY22 is not available in reviewed company decks (entered as 0 = not disclosed in this row; do not chart). FY23 company EBITDA (INR 7.79 Bn) and company net profit (INR 4.97 Bn) exclude the one-time Aleor write-off; S&P net income for FY23 is INR 3.42 Bn — a discrepancy of ~INR 1.55 Bn attributable to that adjustment [IP-Q1FY27 note]. FY26 pre-tax income includes ~INR 670 Mn of unusual/exceptional charges [S&P/SA]; Q4 FY26 alone carried a INR 0.25 Bn exceptional item and a deferred-tax credit of INR 1.14 Bn [IP-Q1FY27; FPJ, May 2026].
6B. Margins (%)
Revenue CAGR FY22–FY26: 8.5% (INR 53.06 Bn → 73.45 Bn). Net income CAGR FY22–FY26: 6.7%. Revenue TTM (Jun 2026): INR 77.84 Bn, +14.1% [S&P/SA].
Note on gross margin: S&P's gross margin (~72%) treats only material cost as cost of revenue; company decks show gross margin of 76% (Q1 FY26), 71% (Q4 FY26) and 71% (Q1 FY27) — the Q1 FY27 compression reflects a 52% YoY jump in material consumption as US volume launches and API mix rose [IP-Q1FY27].
6C. Balance sheet: notes and sources
Notes: FY22 short-term borrowings include INR 2,000 Mn current portion of long-term debt. S&P reports nil intangibles for FY23–FY25 (company may carry small intangibles within PP&E); FY26 intangibles of INR 2,868 Mn principally reflect Utility Therapeutics/Pivya, which the company accounted as an intangible-asset acquisition of USD 25 Mn [PR-Q2FY26 via FilingReader] — note the discrepancy with the USD 12 Mn headline consideration (headline excludes contingent/profit-share components). CRISIL reported liquid surplus of INR 203 Cr at 31 Mar 2026 and 27% average utilisation of fund-based limits over the six months to March 2026 [CRISIL-Jun26].
6D. Cash flow
Company-reported capex (INR Bn): FY23 4.12, FY24 3.45, FY25 5.75, FY26 4.32 [IP-Q1FY27] — consistent with S&P cash capex within ±5%.
6E. Ratios
Methodology: working-capital days computed as year-end balance ÷ revenue × 365 (revenue basis used because S&P's material-only cost of revenue would inflate inventory days to >400). Ratios from [S&P/SA] unless computed. Company ROCE FY22 not disclosed (0 = not available).
6F. Commentary — trends, inflections and drivers
Revenue. Growth has been steady but unspectacular: an 8.5% four-year CAGR, with FY22 (−1.6%) and FY23 (+6.5%) depressed by US price erosion and a COVID-era high base in acute domestic products, then a re-acceleration to 10.2% in FY24 and 10.1% in FY26. The decisive inflection is Q1 FY27: +26% YoY to INR 2,150 Cr, driven by US formulations (+49%), API (+33%) and ex-US (+17%) [PR-Q1FY27]. TTM revenue of INR 77.8 Bn implies the business is now running ~6% ahead of FY26.
Profitability. The FY23 trough (EBIT margin 7.7%) reflected high R&D (12.8% of sales), under-utilised new plants (oncology, injectables, derma) and the Aleor write-off. FY24 recovery came largely from a sharp R&D cut (from INR 7.2 Bn to 4.8 Bn). Since then, EBITDA margins have been stuck in a 15–16% band as R&D was rebuilt (9.6% of FY26 sales) and the US branded launch absorbed SG&A. Pre-R&D EBITDA margin was 25% in Q4 FY26 and 24% in Q1 FY27 [PR-Q4FY26; PR-Q1FY27], indicating the underlying generic engine earns healthy contribution; post-R&D margin was 16% in Q1 FY27 (vs 17% Q1 FY26) as material costs outpaced revenue. Net income growth in FY26 (+15.7%) was flattered by an unusually low tax rate (3.3%), including a INR 114 Cr Q4 deferred-tax credit; on a normalised ~17–18% tax rate, FY26 net income would have been roughly INR 5.7 Bn — essentially flat on FY25. This is the single most important quality-of-earnings caveat.
Balance sheet. Leverage rose meaningfully in FY25: net debt nearly tripled to INR 11.7 Bn as inventory jumped INR 6.4 Bn (stocking ahead of US launches) and receivables rose INR 3.8 Bn; CRISIL explicitly flagged inventory build-up for launches and expected liquidation in FY26 [CRISIL Jul-2025]. FY26 delivered only partial normalisation — inventory still rose INR 2.2 Bn and net debt edged up to INR 12.3 Bn — though net debt/EBITDA improved to 1.12x. The debt is almost entirely short-term (commercial paper and working-capital lines), so refinancing risk is real but mitigated by the AA+/A1+ rating and promoter strength.
Cash flow. FY25 was an outlier year of negative FCF (−INR 4.8 Bn) because of the working-capital build; FY26 FCF recovered to INR 3.5 Bn (FCF/net income 52%). Over five years cumulative FCF (INR 7.6 Bn) covered only ~72% of cumulative dividends (INR 10.6 Bn), with the gap debt-funded — sustainable at current leverage but not indefinitely.
Returns. ROE in the 11–13% range and ROIC of ~11–12% are below large-cap Indian peers and only modestly above cost of capital, reflecting a heavy fixed-asset base (asset turnover <1x). Company-reported ROCE excluding non-deployed assets (15%) suggests idle capacity still burdens reported returns; incremental US launches from existing plants offer operating leverage.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line | Contents | Key products / platforms |
|---|---|---|
India Branded Business | Human branded generics (speciality + acute) and Animal Health | Azithral, Althrocin, Roxid, Wikoryl, Gestofit, Isofit, Travisight; Sharkoferrol, Moxel, Xceft, Mceft (vet) |
US Formulations | US generics (oral solid, derma, ophthalmic, injectable, oncology) and US branded (Pivya, Nuvessa) | 185 commercialised generics; 244 ANDA approvals |
Ex-US Formulations | Generics in Europe, Canada, Australia, Brazil, Chile, South Africa, UAE, SE Asia | Partner and subsidiary-led |
API | Merchant APIs and intermediates | 152 US DMFs; customers in 60+ countries |
Business Lines (Annual)
| Business line | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
India Branded Business (INR Cr) | 1,926 | 2,063 | 2,200 | 2,339 | 2,458 |
US Formulations (INR Cr) | 1,666 | 1,572 | 1,730 | 1,957 | 2,206 |
Ex-US Formulations (INR Cr) | 775 | 852 | 1,052 | 1,243 | 1,494 |
API (INR Cr) | 939 | 1,166 | 1,246 | 1,133 | 1,187 |
Total Revenue from Operations (INR Cr) | 5,306 | 5,653 | 6,228 | 6,672 | 7,345 |
Business Lines (FY2023–FY2026)
| Business line | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
India Branded growth (%) | 7.1 | 6.6 | 6.3 | 5.1 |
US Formulations growth (%) | -5.6 | 10.1 | 13.1 | 12.7 |
Ex-US Formulations growth (%) | 9.9 | 23.5 | 18.2 | 20.2 |
API growth (%) | 24.2 | 6.9 | -9.1 | 4.8 |
Total growth (%) | 6.5 | 10.2 | 7.1 | 10.1 |
Business Lines (FY2024–FY2026)
| Business line | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India Branded share (%) | 35.3 | 35.1 | 33.5 |
US Formulations share (%) | 27.8 | 29.3 | 30.0 |
Ex-US Formulations share (%) | 16.9 | 18.6 | 20.3 |
API share (%) | 20.0 | 17.0 | 16.2 |
Business Lines (Quarterly)
| Business line | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
India Branded (INR Cr) | 599 | 639 | 652 | 568 | 642 |
US Formulations (INR Cr) | 523 | 566 | 554 | 564 | 778 |
Ex-US Formulations (INR Cr) | 328 | 392 | 406 | 369 | 383 |
API (INR Cr) | 261 | 314 | 264 | 347 | 346 |
Total (INR Cr) | 1,711 | 1,911 | 1,876 | 1,848 | 2,150 |
Revenue by Segment
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Animal Health revenue (INR Mn) | 2,320 | 2,806 | 3,553 | 4,305 | 5,191 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 53,058 | 56,526 | 62,286 | 66,721 | 73,449 |
Gross profit (INR Mn) | 38,076 | 38,778 | 44,325 | 47,912 | 52,660 |
Operating income / EBIT (INR Mn) | 5,875 | 4,378 | 6,607 | 7,298 | 7,970 |
EBITDA — S&P basis (INR Mn) | 8,585 | 6,962 | 9,141 | 9,891 | 10,978 |
EBITDA — company reported (INR Mn) | 0 | 7,790 | 9,610 | 10,530 | 11,770 |
Pre-tax income (INR Mn) | 6,254 | 3,546 | 6,318 | 7,072 | 6,940 |
Income tax (INR Mn) | 1,045 | 126 | 160 | 1,252 | 231 |
Net income attributable (INR Mn) | 5,209 | 3,420 | 6,158 | 5,834 | 6,748 |
EPS basic (INR) | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 |
EPS diluted (INR) | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 |
Dividend per share (INR) | 10 | 8 | 11 | 11 | 12 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 71.8 | 68.6 | 71.2 | 71.8 | 71.7 |
Operating (EBIT) margin (%) | 11.1 | 7.7 | 10.6 | 10.9 | 10.9 |
EBITDA margin S&P basis (%) | 16.2 | 12.3 | 14.7 | 14.8 | 14.9 |
EBITDA margin company reported (%) | 0 | 14 | 15 | 16 | 16 |
Net margin (%) | 9.8 | 6.1 | 9.9 | 8.7 | 9.2 |
Effective tax rate (%) | 16.7 | 3.6 | 2.5 | 17.7 | 3.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 71,220 | 61,828 | 64,456 | 77,729 | 87,626 |
Cash and equivalents (INR Mn) | 611 | 755 | 1,202 | 835 | 1,964 |
Short-term borrowings (INR Mn) | 6,300 | 6,359 | 4,305 | 11,956 | 12,389 |
Long-term borrowings (INR Mn) | 0 | 0 | 0 | 0 | 1,219 |
Lease liabilities (INR Mn) | 871 | 862 | 827 | 619 | 691 |
Total debt incl. leases (INR Mn) | 7,171 | 7,220 | 5,132 | 12,575 | 14,299 |
Net debt (INR Mn) | 6,560 | 6,465 | 3,930 | 11,740 | 12,336 |
Shareholders' equity (INR Mn) | 52,376 | 43,705 | 48,182 | 51,895 | 56,690 |
Goodwill and intangibles (INR Mn) | 1,548 | 0 | 0 | 0 | 2,868 |
Inventory (INR Mn) | 16,097 | 14,753 | 16,435 | 22,881 | 25,106 |
Trade receivables (INR Mn) | 8,071 | 10,464 | 10,248 | 13,998 | 14,663 |
Trade payables (INR Mn) | 7,064 | 6,798 | 7,356 | 8,799 | 8,351 |
Working capital (INR Mn) | 11,443 | 12,731 | 16,236 | 16,755 | 19,788 |
Capital work-in-progress (INR Mn) | 22,058 | 6,013 | 5,244 | 8,372 | 6,337 |
Book value per share (INR) | 266.46 | 222.34 | 245.12 | 264.09 | 288.70 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn) | 5,524 | 7,240 | 8,032 | 880 | 7,827 |
Capital expenditure (INR Mn) | 4,256 | 4,434 | 3,275 | 5,636 | 4,346 |
Free cash flow (INR Mn) | 1,267 | 2,805 | 4,757 | -4,757 | 3,481 |
Dividends paid (INR Mn) | 2,752 | 1,966 | 1,573 | 2,162 | 2,162 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Change in working capital (INR Mn) | -3,673 | -576 | -957 | -9,214 | -2,568 |
Intangibles purchased (INR Mn) | 0 | 0 | 0 | 0 | 603 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 10.1 | 7.1 | 13.4 | 11.6 | 12.4 |
ROA (%) | 5.3 | 4.1 | 6.5 | 6.4 | 6.0 |
ROIC (%) | 8.7 | 7.7 | 12.6 | 10.4 | 11.6 |
ROCE S&P (%) | 10.9 | 9.6 | 13.2 | 13.6 | 12.9 |
ROCE company, ex non-deployed assets (%) | 0 | 14 | 15 | 16 | 15 |
Current ratio (x) | 1.67 | 1.78 | 2.12 | 1.70 | 1.76 |
Debt / equity (x) | 0.14 | 0.17 | 0.11 | 0.24 | 0.25 |
Net debt / EBITDA (x) | 0.76 | 0.93 | 0.43 | 1.19 | 1.12 |
Interest coverage EBIT/interest (x) | 33.1 | 8.7 | 11.8 | 9.3 | 8.5 |
Asset turnover (x) | 0.77 | 0.85 | 0.99 | 0.94 | 0.89 |
Receivable days (revenue basis) | 55.5 | 67.6 | 60.1 | 76.6 | 72.9 |
Inventory days (revenue basis) | 110.7 | 95.3 | 96.3 | 125.2 | 124.8 |
Payable days (revenue basis) | 48.6 | 43.9 | 43.1 | 48.1 | 41.5 |
Cash conversion cycle (revenue basis, days) | 117.6 | 119.0 | 113.3 | 153.7 | 156.2 |
Dividend payout (cash basis, %) | 52.8 | 57.5 | 25.5 | 37.1 | 32.0 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India — branded formulations (INR Cr) | 2,200 | 2,339 | 2,458 |
United States — formulations (INR Cr) | 1,730 | 1,957 | 2,206 |
Rest of World — formulations (INR Cr) | 1,052 | 1,243 | 1,494 |
Global API — India + export (INR Cr) | 1,246 | 1,133 | 1,187 |
Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India branded growth (%) | 6.6 | 6.3 | 5.1 |
United States growth (%) | 10.1 | 13.1 | 12.7 |
Rest of World growth (%) | 23.5 | 18.2 | 20.2 |
Global API growth (%) | 6.9 | -9.1 | 4.8 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Closing share price (INR) | 696.10 | 473.08 | 949.00 | 906.05 | 653.53 |
Market capitalisation (INR Mn) | 145,771 | 97,564 | 193,575 | 182,755 | 130,370 |
Enterprise value (INR Mn) | 151,109 | 104,548 | 200,785 | 192,124 | 143,795 |
P/E (x) | 27.98 | 28.53 | 31.43 | 31.33 | 19.32 |
EV/EBITDA (x) | 17.60 | 15.02 | 21.97 | 19.42 | 13.10 |
EV/Sales (x) | 2.85 | 1.85 | 3.22 | 2.88 | 1.96 |
P/B (x) | 2.78 | 2.23 | 4.02 | 3.52 | 2.30 |
Dividend yield (%) | 1.44 | 1.69 | 1.16 | 1.21 | 1.84 |
Share Price & Returns
| Horizon | Return | Basis / source |
|---|---|---|
Since FY26 year-end (31 Mar 2026) | ~+23% (653.53 → ~803) | Computed |
1 year | ~−13% to −20% (reported mid-2026 readings) | Bajaj Broking; EquityPandit (14 Jul 2026) |
~3.5 years (since 31 Mar 2023) | ~+70% (473.08 → ~803) | Computed |
~4.5 years (since 31 Mar 2022) | ~+15% (696.10 → ~803) | Computed |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 10 | 8 | 11 | 11 | 12 |
Dividends paid in following year (INR Mn) | 1966 | 1,573 | 2,162 | 2,162 | 2,360 |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
CRISIL | Long-term bank facilities (INR 1,100 Cr) | AA+ | Stable | 30 Jun 2026 |
CRISIL | Commercial paper (INR 1,100 Cr) | A1+ | — | 30 Jun 2026 |
CARE | Commercial paper | A1+ | — | Per CP offer document (Dec 2025) |
Moody's / S&P / Fitch | — | Not rated | — | — |
Analyst Conclusions
Management guidance (FY27). Consolidated revenue growth in the mid-teens (raised from 10–12%); US generics growth mid-to-high teens (raised from low teens); 15+ US launches; R&D ~9–10% of revenue; continued investment in US branded and peptide pipeline [IP-Q1FY27; Q1 FY27 call].
Implied FY27 revenue on guidance: ~INR 8,350–8,450 Cr (mid-teens on INR 7,345 Cr).
Bull case.
-
US launch super-cycle on existing capacity. Q1 FY27 US revenue +49% with 7 launches, 15+ guided for the year, plus Para IV exclusivities (Larotrectinib, Binimetinib, Dapagliflozin) should lift utilisation of plants built in 2020–23, driving EBITDA margins from 16% toward pre-R&D-leveraged high-teens.
-
Re-rating from trough multiples. At 20x forward earnings and 15x EV/EBITDA, the stock trades at roughly half the Indian pharma median multiple despite AA+ credit, a 1.5% yield and accelerating growth; sustained mid-teens growth could close part of that gap.
-
Compliance overhang removed. EIRs across key sites and a zero-483 unannounced BE inspection (Sep 2026) reduce the tail risk that has historically de-rated Indian generic names.
Bear case.
-
Earnings quality and normalised growth. FY26 PAT growth of 16% relied on a 3.3% tax rate and a INR 114 Cr deferred-tax credit; at normal tax, FY26 earnings were flat, and Q1 FY27 PAT grew only 12% on 26% revenue growth as margins compressed.
-
Working capital and leverage. Inventory of INR 25.1 Bn (~125 days of sales) and ~INR 12.4 Bn of short-term debt mean US launch growth could again consume cash, as in FY25 (FCF −INR 4.8 Bn).
-
Structural India underperformance and US branded risk. India Branded is growing ~3 points below the market with share slipping; the US branded foray is tiny and SG&A-hungry, with limited evidence of commercial traction yet.
Key catalysts and monitorables (next 12 months).
Analyst verdict. Alembic Pharmaceuticals enters the second half of FY27 at a genuine operational inflection, but the investment case still hinges on converting revenue momentum into cash and margin. The evidence for the inflection is strong: Q1 FY27 revenue grew 26%, US formulations 49% and API 33%; management raised full-year guidance to mid-teens growth; and the regulatory slate is unusually clean after EIRs at the Karkhadi injectables plant and a zero-observation unannounced inspection of the BE centre that had drawn a July warning letter. A portfolio of 244 ANDA approvals, three oncology/diabetes exclusivity opportunities and 15+ planned US launches give the generic engine visible fuel, and much of the capacity needed to serve it has already been built and paid for.
The counter-evidence is equally concrete. Reported FY26 profit growth was tax-assisted; post-R&D EBITDA margins have not moved beyond 16% in three years; the cash conversion cycle has widened by roughly 40 days since FY24; and almost all borrowings are short-term. India — historically the cash cow — is growing below the market and ceding share, while the US branded venture is too small to move consolidated numbers for at least several quarters and will weigh on SG&A in the interim.
Net, Alembic screens as a reasonably priced, credit-strong, promoter-anchored mid-cap whose discount to sector multiples reflects legitimate concerns about returns (ROIC ~11–12%) rather than mispricing alone. The risk-reward is constructive if — and only if — the next two to three quarters demonstrate operating leverage (EBITDA margin expanding toward 18%), positive free cash flow despite launch inventory, and stabilisation of India share. Investors should treat Q2–Q3 FY27 gross margin, inventory days and Pivya/Nuvessa traction as the decisive tests; a pass on all three would support a re-rating, while a miss on cash conversion would confirm the "growth without returns" pattern of FY22–FY26.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | On board since | Born / age | Background | Committees |
|---|---|---|---|---|---|
Chirayu R. Amin | Executive Chairman (CEO until 31 Mar 2026); promoter | 16 Jun 2010 (re-appointed 1 Apr 2021) | 4 Dec 1946 / 79 | MBA (USA); directorships in Alembic Ltd, Paushak Ltd, Shreno Ltd, Nirayu Ltd | — |
Pranav C. Amin | Managing Director (heads international business) | 31 Mar 2011; MD since 2016 | 5 Oct 1975 / 51 | — | SRC member; RMC member |
Shaunak C. Amin | Managing Director (heads India Branded Business) | 2 May 2013 | 1 May 1978 / 48 | — | — |
Raj Kumar Baheti | Non-Executive Non-Independent Director (from 1 Apr 2026; earlier Executive Director and CFO) | 16 Jun 2010 | 24 Oct 1959 / 66 | Commerce graduate; Fellow, ICAI | SRC member; RMC member |
Ashok Kumar Barat | Independent Director | 10 Feb 2022 | 5 Dec 1956 / 69 | Holds 7 listed directorships | Audit Committee Chair (from 4 Feb 2025); RMC Chair; NRC member |
Jai Shishir Diwanji | Independent Director | 5 May 2023 | 4 Feb 1973 / 53 | 5 listed directorships | SRC Chair; Audit and NRC member |
Manish S. Kejriwal | Independent Director | 31 Mar 2024 | 8 Nov 1968 / 57 | Private equity investor; company profile describes co-chairing CII's PE/VC committee and SEBI alternative investments advisory role | NRC Chair (from 4 Feb 2025) |
Geeta A. Goradia | Independent Director | 3 Feb 2025 | 19 Sep 1953 / 73 | Prior independent directorships incl. Panasonic Energy India | Audit and NRC member |
Sujit J. Bhayani | Independent Director | 18 Jun 2026 (5-year term) | — | — | Not yet disclosed |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Since | Notes |
|---|---|---|---|
G. Krishnan | Chief Financial Officer | 7 Jul 2025 | Succeeded R.K. Baheti as CFO [FY26 Directors' Report] |
Chirag Shukla | Company Secretary & Compliance Officer | 20 Aug 2026 | Replaced Manisha Saraf (resigned 10 Aug 2026) |
Tushar Mehta | Head – R&D | 3 Jun 2026 | New appointment |
Ramesh Juneja | Senior Management Personnel | 1 Jun 2026 | Role not specified in filing |
Ajay Kumar Desai | SVP – Finance | — | IR contact on FY26 release |
Craig Salmon | President, Alembic Pharmaceuticals Inc. (US) | — | Leads US business |
Dr. Sachin Ghosalkar | SVP – Supply Chain & Operations | — | RMC invitee |
Ish Bansal | Head – Business Development | — | RMC invitee |
Isha Lamba | Investor Relations | — | IR contact |
Executive Leadership Team (Annual)
| Executive | FY2024 total (INR Mn) | FY2025 total (INR Mn) |
|---|---|---|
Chirayu R. Amin | 193.8 | 141.0 |
Shareholding Trend
| Holder category | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|
Promoters (%) | 69.68 | 69.74 | 69.74 | 69.74 | 69.87 |
Mutual funds (%) | 9.05 | 8.55 | 8.22 | 8.18 | 8.73 |
Foreign institutions (%) | 3.96 | 4.05 | 4.24 | 4.25 | 4.17 |
Other domestic institutions (%) | 7.41 | 7.75 | 7.95 | 8.00 | 7.20 |
Retail and others (%) | 9.90 | 9.92 | 9.85 | 9.83 | 10.03 |
Major Shareholders
| Holder | Stake (%) | Type | Source |
|---|---|---|---|
Nirayu Pvt Ltd | 35.65 | Promoter | MarketsMojo, Jun 2026 |
Alembic Ltd | 28.54 | Promoter | ICRA rationale on Alembic Ltd, Aug 2026 |
Life Insurance Corporation of India | 4.32 | Institution | MarketsMojo, Jun 2026 |
Chirayu R. Amin (direct) | ~2.55 | Promoter/insider | Simply Wall St |
Alembic City Ltd | — | Promoter group | Trendlyne list |
DSP Midcap Fund | — | Mutual fund | MarketsMojo list |
Kotak Small Cap Fund | — | Mutual fund | MarketsMojo list |
ICICI Prudential Pharma Healthcare & Diagnostics Fund | — | Mutual fund | MarketsMojo list |
Tata AIA Life (Unit Linked Multi Cap) | — | Insurance | MarketsMojo list |
141–179 FIIs combined | ~4.2 | Foreign | MarketsMojo / Trendlyne |
Competitive Landscape
Competitors by Segment
| Business | Competitors (named) |
|---|---|
India branded (human) | Sun Pharma, Cipla, Mankind Pharma, Torrent Pharma, Lupin, Zydus Lifesciences, Alkem Laboratories, Abbott India, Intas (unlisted), Macleods (unlisted), Ipca, Ajanta, Glenmark |
India animal health | Zoetis, Elanco, Virbac, MSD Animal Health, Indian Immunologicals (most unlisted in India) |
US generics | Aurobindo, Zydus, Lupin, Dr. Reddy's, Sun Pharma, Glenmark, Torrent, Cipla, Teva, Viatris, Amneal, Hikma |
Ex-US generics | Aurobindo, Torrent (Brazil), Glenmark, Sandoz, Teva and local players |
API | Divi's, Aurobindo, Ipca, Granules, Laurus, Chinese API producers |
US branded women's health/UTI | Branded and generic anti-infective makers; Exeltis; others (not exhaustively verified) |
Peer Comparison FY2026
| Company | FY26 revenue (INR Cr) | YoY growth (%) | Notes |
|---|---|---|---|
Sun Pharma | 58,462 | 11.2 | Largest Indian pharma |
Aurobindo Pharma | 33,653 | 6.1 | US generics heavy |
Zydus Lifesciences | 27,658 | 19.0 | — |
Torrent Pharma | 13,980 | 21.4 | Incl. JB Pharma consolidation |
Ipca Laboratories | 9,646 | 7.9 | Closest India/API peer |
Alembic Pharmaceuticals | 7,345 | 10.1 | Subject |
Ajanta Pharma | 5,453 | 17.3 | Branded EM peer |
Peer Comparison FY2026 — Revenue
| Metric | Alembic | Torrent Pharma | Ipca Labs | Ajanta Pharma |
|---|---|---|---|---|
Revenue (INR Cr) | 7,345 | 13,980 | 9,646 | 5,453 |
Revenue growth (%) | 10.1 | 21.4 | 7.9 | 17.3 |
EBITDA margin (%) | 16.0 | 32.6 | — | — |
Net margin (%) | 9.2 | 15.3 | — | — |
R&D intensity (%) | 9.6 | — | — | — |
P/E (x, snapshot) | 23.2 | 77.6 | 39.2 | 39.9 |



